Abstract
In this issue of Blood, Goy et al report on the promising activity of a phase 1b trial of the targeted therapy triplet rituximab, ibrutinib, and lenalidomide in patients with relapsed nongerminal center diffuse large B-cell lymphoma (DLBCL).1.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 996-998 |
| Number of pages | 3 |
| Journal | Blood |
| Volume | 134 |
| Issue number | 13 |
| DOIs | |
| State | Published - Sep 26 2019 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology